Ontario puts C$5M into 10 life sciences and healthtech startups
What's the deal? The Government of Ontario is investing C$5M across 10 early-stage life sciences and healthtech companies, each receiving C$500,000. Recipients include Kare Chemical Technologies, which is turning orange peels into non-psychoactive treatments for epilepsy and chronic pain; Myomar Molecular, building a diagnostic tool to measure muscle atrophy; and Stoked Bio, developing novel anti-infectives and cancer therapeutics.
Other recipients are Esphera SynBio, myStoria, mDetect, NodeAI, ScriptRunner Innovations, Synakis, and Synmedix. The funding is meant to help these companies turn discoveries and prototypes into products.
Why now? This is the fourth round of investments through Ontario's Life Sciences Innovation Fund (LSIF), delivered by the Ontario Centre of Innovation (OCI). The province launched the fund in 2022 with C$15M. That initial pot is now fully deployed, and Ontario's 2025 budget renewed it with an additional C$15M over three years.
The announcement also comes a week after Ontario committed up to C$5M to help French biopharma giant SanofiDealroom has a profile for this one. Try Dealroom → expand its AI centre of excellence in Toronto — part of a broader push to reinforce the province's position as a global life sciences hub.
What could go wrong? The LSIF targets startups that have raised less than C$3M in third-party funding and are currently raising pre-seed or seed rounds. At that stage, failure rates are high, and C$500,000 alone won't carry most companies to commercialisation. The fund's value depends on whether it can genuinely derisk these startups enough to attract follow-on capital.
Some industry leaders believe Canada's life sciences sector is at a "generational moment," but disagree on what governments should actually do to support its growth — raising questions about whether cheques of this size move the needle.
The signal: Ontario's LSIF renewals sit alongside a growing pattern of provincial and corporate commitment to the region's life sciences corridor — Sanofi's concurrent C$5M AI centre expansion in Toronto underscores that multinationals see the talent base worth investing in. The test for these C$500,000 cheques is whether they can bridge pre-seed startups to the kind of follow-on rounds that turn a government programme into a genuine dealflow pipeline for private investors.
Read more: betakit.com
